肾脏病中铁死亡的病理生理机制和药物疗法研究进展  

Researches progress on the pathogenesis mechanism of ferroptosis and pharmacotherapy in kidney diseases

作　　者：赖玮婧[1] 黄蓉双 王波[2] 付平[2] 马良[2] Lai Weijing;Huang Rongshuang;Wang Bo;Fu Ping;Ma Liang(Department of Nephrology,the First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,China;Kidney Research Institute,Department of Nephrology,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]成都医学院第一附属医院肾病科,成都610500 [2]四川大学华西医院肾脏病研究所华西医院肾脏内科,成都610041

出　　处：《中华肾脏病杂志》2024年第5期411-417,共7页Chinese Journal of Nephrology

基　　金：国家自然科学基金(82370737);四川省科技厅项目(2020YFQ0055、2022YFS0589、2022YFS0328);四川省医学会项目(S23024)。

摘　　要：铁死亡是一种铁依赖的程序性细胞死亡,细胞内铁过载和脂质活性氧蓄积对铁死亡的发生发展起核心促进作用,任何影响铁代谢和氧化还原系统平衡的因素都可能诱发加重铁死亡。铁死亡参与急性肾损伤、糖尿病肾病、肾间质纤维化等诸多肾脏病的病理过程,且抑制铁死亡具有肾脏保护作用。该文系统综述铁死亡的病理生理机制及其在肾脏病中的研究进展,探讨靶向铁死亡在肾脏病治疗中的应用前景。Ferroptosis is an iron-dependent programmed cell death.Iron overload and lipid reactive oxygen accumulation play a core role in the occurrence and development of ferroptosis.Any factors affecting the balance of iron metabolism and redox system may induce and aggravate ferroptosis.Ferroptosis is involved in the pathological process of acute kidney injury,diabetic nephropathy,renal interstitial fibrosis and some other kidney diseases,and inhibiting ferroptosis has potential renoprotective benefits.This article reviewed the pathophysiological mechanism of ferroptosis and its research progress in renal diseases,and discussed the application prospect of targeted ferroptosis in the treatment of renal diseases.

关 键 词：铁死亡 肾疾病 药物疗法 机制 

分 类 号：R692[医药卫生—泌尿科学]